BWAY vs. IRMD, EMBC, RXST, BBNX, CBLL, DCTH, AVNS, BFLY, BVS, and KIDS
Should you be buying BrainsWay stock or one of its competitors? The main competitors of BrainsWay include Iradimed (IRMD), Embecta (EMBC), RxSight (RXST), Beta Bionics (BBNX), CeriBell (CBLL), Delcath Systems (DCTH), Avanos Medical (AVNS), Butterfly Network (BFLY), Bioventus (BVS), and OrthoPediatrics (KIDS). These companies are all part of the "medical equipment" industry.
BrainsWay vs.
BrainsWay (NASDAQ:BWAY) and Iradimed (NASDAQ:IRMD) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, media sentiment, analyst recommendations, community ranking, profitability, risk, valuation, institutional ownership and dividends.
30.1% of BrainsWay shares are owned by institutional investors. Comparatively, 92.3% of Iradimed shares are owned by institutional investors. 19.0% of BrainsWay shares are owned by company insiders. Comparatively, 36.8% of Iradimed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
BrainsWay has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, Iradimed has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500.
In the previous week, BrainsWay had 4 more articles in the media than Iradimed. MarketBeat recorded 6 mentions for BrainsWay and 2 mentions for Iradimed. Iradimed's average media sentiment score of 1.83 beat BrainsWay's score of 0.72 indicating that Iradimed is being referred to more favorably in the news media.
Iradimed has a net margin of 26.26% compared to BrainsWay's net margin of 3.88%. Iradimed's return on equity of 24.12% beat BrainsWay's return on equity.
Iradimed has higher revenue and earnings than BrainsWay. Iradimed is trading at a lower price-to-earnings ratio than BrainsWay, indicating that it is currently the more affordable of the two stocks.
BrainsWay currently has a consensus target price of $14.25, indicating a potential upside of 37.02%. Iradimed has a consensus target price of $72.00, indicating a potential upside of 35.31%. Given BrainsWay's higher possible upside, equities analysts plainly believe BrainsWay is more favorable than Iradimed.
Iradimed received 191 more outperform votes than BrainsWay when rated by MarketBeat users. However, 67.31% of users gave BrainsWay an outperform vote while only 65.58% of users gave Iradimed an outperform vote.
Summary
Iradimed beats BrainsWay on 11 of the 17 factors compared between the two stocks.
Get BrainsWay News Delivered to You Automatically
Sign up to receive the latest news and ratings for BWAY and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BrainsWay Competitors List
Related Companies and Tools
This page (NASDAQ:BWAY) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy BWAY Stock Free BWAY Stock Alerts